top of page

Our Highlights

Stay up to date with the latest news

December 2025.
Our first publication!

PapMV nanoparticles: A novel pathway to SARS-CoV-2 protection, distinct from Imidazoquinolines.​

October 2025.
"Groundbreaking discoveries"

VaxSynergy is made possible through the support of Médicament Québec and the collaboration of our industrial and strategic partners.​​

bottom of page